Sprint Bioscience AB (publ)

OM:SPRINT Stock Report

Market Cap: SEK 59.9m

Sprint Bioscience Valuation

Is SPRINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SPRINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 29.13
Fair Value
98.1% undervalued intrinsic discount
1
Number of Analysts

Below Fair Value: SPRINT (SEK0.56) is trading below our estimate of fair value (SEK29.13)

Significantly Below Fair Value: SPRINT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPRINT?

Key metric: As SPRINT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SPRINT. This is calculated by dividing SPRINT's market cap by their current revenue.
What is SPRINT's PS Ratio?
PS Ratio0.9x
SalesSEK 62.38m
Market CapSEK 59.93m

Price to Sales Ratio vs Peers

How does SPRINT's PS Ratio compare to its peers?

The above table shows the PS ratio for SPRINT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.3x
NICA Nanologica
7.3x66.61%SEK 132.1m
BIOVIC B Biovica International
7.6x72.19%SEK 69.2m
LPGO Lipigon Pharmaceuticals
2.4x104.89%SEK 22.0m
ACOU AcouSort
8x60.28%SEK 76.6m
SPRINT Sprint Bioscience
0.9x12.64%SEK 59.9m

Price-To-Sales vs Peers: SPRINT is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (6.3x).

Price to Sales Ratio vs Industry

How does SPRINT's PS Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.9x14.6%
SPRINT Sprint Bioscience
 0.9x12.64%US$6.26m
XBRANE Xbrane Biopharma
1.5x24.95%US$45.41m
SENZA SenzaGen
2.7xn/aUS$16.51m
SPRINT 0.9xIndustry Avg. 9.9xNo. of Companies10PS01224364860+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.9x25.1%
SPRINT Sprint Bioscience
 0.9xn/aUS$6.26m
No more companies

Price-To-Sales vs Industry: SPRINT is good value based on its Price-To-Sales Ratio (0.9x) compared to the Swedish Biotechs industry average (9.9x).

Price to Sales Ratio vs Fair Ratio

What is SPRINT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPRINT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: SPRINT is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget
Consensus Narrative from 1 Analyst
SEK 2.00
Fair Value
72.0% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/28 19:23
End of Day Share Price 2025/07/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sprint Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siri LadowDanske Bank
Johan UnnerusRedeye